Publications by authors named "Sue Naim"

Claim this Profile
C
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail J Roboz, Sue Naim

Leukemia· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail J Roboz, Sue Naim

Leukemia· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Amit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D Roman, Sue Naim

Clin Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Daniela Matei, Sharad Ghamande, Lynda Roman, Angeles Alvarez Secord, John Nemunaitis, Sue Naim

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Jean-Pierre J Issa, Gail Roboz, David Rizzieri, Elias Jabbour, Wendy Stock, Sue Naim

Lancet Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Yun-Jung Choi, Brian K Roberts, Xueyan Wang, J Casey Geaney, Sue Naim

Atherosclerosis· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
Harold E Bays, Sherwyn Schwartz, Thomas Littlejohn, Boris Kerzner, Ronald M Krauss, Sue Naim

J Clin Endocrinol Metab· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis